Aspirin for cardiovascular disease prevention

Medical Journal of Australia

Volumn 179, Issue 3, 2003, Pages 147-152

  Hung, Joseph ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; DIPYRIDAMOLE; FIBRINOGEN RECEPTOR ANTAGONIST; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; STREPTOKINASE; WARFARIN;

ACUTE HEART INFARCTION; ARTERY DISEASE; BLEEDING; BLOOD PRESSURE MONITORING; BRAIN HEMORRHAGE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DILATATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG POTENTIATION; EATING HABIT; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART VALVE PROSTHESIS; HUMAN; ISCHEMIC HEART DISEASE; LIFESTYLE; LOW DRUG DOSE; LOWER LEG; MONOTHERAPY; PEPTIC ULCER; PERIPHERAL ISCHEMIA; PHYSICAL ACTIVITY; PRIMARY PREVENTION; REVIEW; SECONDARY PREVENTION; SKIN BRUISING; SMOKING CESSATION; STABLE ANGINA PECTORIS; UNSTABLE ANGINA PECTORIS;

EID: 0042388468     PISSN: 0025729X     EISSN: None     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2003.tb05474.x     Document Type: Review

References (27)

1. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Antithrombotic Trialists' Collaboration. BMJ 2002; 324: 71-86.
2. National Health and Medical Research Council. A Guide to the Development, Implementation and Evaluation of Clinical Practice Guidelines. Canberra: NHMRC, AusInfo, 1999.
3. Hayden M, Pignone M, Phillips C, Mulrow C. Aspirin for the primary prevention of cardiovascular events: A summary of the evidence for the US Preventive Services Task Force. Ann Intern Med 2002; 136: 161-172.
4. Randomised trial of intravenous streptokinase, oral aspirin, both or neither among 17 187 cases of suspected acute myocardial infarction: ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet 1988; 2: 349-360.
5. Chen ZM, Sandercock P, Pan HC, et al. Indications for early aspirin use in acute ischemic stroke: A combined analysis of 40 000 randomized patients from the Chinese Acute Stroke Trial and the International Stroke Trial. On behalf of the CAST and IST collaborative groups. Stroke 2000; 31: 1240-1249.
6. Mangano DT, for the Multicenter Study of Perioperative Ischemia Research Group. Aspirin and mortality from coronary bypass surgery. N Engl J Med 2002; 347: 1309-1317.
7. Collaborative overview of randomised trials of antiplatet therapy - II: Maintenance of vascular graft or arterial patency by antiplatelet therapy. BMJ 1994; 308: 159-168.
8. Peto R, Gray R, Collins R, et al. Randomised trial of prophylactic daily aspirin in British male doctors. BMJ 1988; 296: 313-316.
9. Final report on the aspirin component of the ongoing Physicians' Health Study. Steering Committee of the Physicians' Health Study Research Group. N Engl J Med 1989; 321: 129-135.
10. Thrombosis prevention trial: Randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. The Medical Research Council's General Practice Research Framework. Lancet 1998; 351: 233-241.
11. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998; 351: 1755-1762.
12. Low-dose aspirin and vitamin E in people at cardiovascular risk: A randomised trial in general practice. Collaborative Group of the Primary Prevention Project. Lancet 2001; 357: 89-95.
13. Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336: 973-979.
14. Rexrode KM, Lee IM, Cook NR, et al. Baseline characteristics of participants in the Women's Health Study. J Womens Health Gender-Based Med 2000; 9: 19-27.
15. Pearson TA, Blair SN, Daniels SR, et al. AHA Guidelines for primary prevention of cardiovascular disease and stroke. 2002 update: Consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation 2002; 106: 388-391.
16. Hankey GJ. Non-valvular atrial fibrillation and stroke prevention. Med J Aust 2001; 174: 234-239.
17. Stein PD, Alpert JS, Bussey HI, et al. Antithrombotic therapy in patients with mechanical and biological prosthetic valves. Chest 2001; 119(1 Suppl): 220S-227S.
18. Massel D, Little SH. Risks and benefits of adding anti-platelet therapy to warfarin among patients with prosthetic heart valves: A meta-analysis. J Am Coll Cardiol 2001; 37: 569-578.
19. Derry S, Loke YK. Risk of gastrointestinal haemorrhage with long term use of aspirin: A meta-analysis. BMJ 2000; 321: 1183-1187.
20. Baker RI. Antiplatelet drugs. Med J Aust 1999; 170: 379-382.
21. He J, Whelton PK, Vu B, Klag MJ. Aspirin and risk of hemorrhagic stroke: A meta-analysis of randomized controlled trials. JAMA 1998; 280: 1930-1935.
22. FitzGerald GA. Parsing an enigma: The pharmacodynamics of aspirin resistance. Lancet 2003; 361: 542-544.
23. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329-1339.
24. Effects of clopidogrel in addition to aspirin in patients with non-ST segment elevation acute coronary syndromes. CURE Study Investigators. N Engl J Med 2001; 345: 494-502.
25. Cairns JA. Oral anticoagulants or aspirin after myocardial infarction. Lancet 1994; 343; 497-498.
26. Hurlen R, Abdelnoor M, Smith P, et al. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med 2002; 347: 969-974.
27. Van Es RF, Jonker JJ, Vergheut FW, et al. Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): A randomised controlled trial. Lancet 2002; 260: 109-113.